Personalized medicine, the inevitable future of cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Personalized medicine, the inevitable future of cancer immunotherapy

Published:2023-09 Issue:5 Volume:20 Page:413-416
ISSN:1741-0541
Container-title:Personalized Medicine
language:en
Short-container-title:Personalized Medicine

Author:

Basiri Mohsen¹²^ORCID

Affiliation:

1. T Cell Therapeutics Research Labs, Cellular Immunotherapy Center, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA

2. Department of Stem Cells & Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology & Technology, ACECR, Tehran, 193954644, Iran

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pme-2023-0083

Reference20 articles.

1. Tumour heterogeneity and resistance to cancer therapies

2. Why the Outcome of Anti‐Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers

3. Immune Checkpoint Inhibitors in Cancer Therapy

4. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RefAI: a GPT-powered retrieval-augmented generative tool for biomedical literature recommendation and summarization;Journal of the American Medical Informatics Association;2024-06-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP